Open AccessGlucose-Functionalized Silver Nanoparticles as a Potential New Therapy Agent Targeting Hormone-Resistant Prostate Cancer cells
Author(s) -
Mariana Morais,
Vera Machado,
Francisca Dias,
Patrícia Figueiredo,
Carlos Palmeira,
Gabriela Martins,
Rui Fernandes,
Ana Rita Malheiro,
Kirsi S. Mikkonen,
Ana Luísa Teixeira,
Rui Medeiros
Publication year - 2022
Publication title -
international journal of nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s364862
Subject(s) - lncap , surface modification , silver nanoparticle , cancer cell , hela , apoptosis , chemistry , cell cycle , endocytosis , prostate cancer , biophysics , cell culture , cell , cancer research , microbiology and biotechnology , materials science , nanotechnology , biology , cancer , biochemistry , nanoparticle , medicine , genetics
Silver nanoparticles (AgNPs) have shown great potential as anticancer agents, namely in therapies' resistant forms of cancer. The progression of prostate cancer (PCa) to resistant forms of the disease (castration-resistant PCa, CRPC) is associated with poor prognosis and life quality, with current limited therapeutic options. CRPC is characterized by a high glucose consumption, which poses as an opportunity to direct AgNPs to these cancer cells. Thus, this study explores the effect of glucose functionalization of AgNPs in PCa and CRPC cell lines (LNCaP, Du-145 and PC-3).